Kerwin, Edward M.
Spangenthal, Selwyn
Kollar, Christine
St Rose, Earl
Reisner, Colin
Funding for this research was provided by:
Pearl Therapeutics Inc., a member of the AstraZeneca Group
Article History
Received: 19 December 2017
Accepted: 13 February 2018
First Online: 5 March 2018
Ethics approval and consent to participate
: This study was conducted in accordance with Good Clinical Practice Guidelines including the International Conference on Harmonisation, the US Code of Federal Regulations, and the Declaration of Helsinki. An institutional review board (Independent Investigational Review Board, Inc., FL, USA; IRB00003563) approved the protocol and informed consent form, and written informed consent was obtained from patients prior to screening.
: Not applicable.
: EMK has served on advisory boards, speaker panels, or received travel reimbursement from Amphastar, AstraZeneca, Forest, Mylan, Novartis, Oriel, Sunovion, Teva, and Theravance. He has conducted multicenter clinical trials for ~ 40 pharmaceutical companies.SS serves on the speaker’s bureau for Boehringer Ingelheim, Mylan, Pearl – A member of the AstraZeneca Group, and Sunovion.CK has no potential conflicts of interest to disclose.ESR is an employee of Pearl – A member of the AstraZeneca Group.CR is Chief Executive Officer of Pearl – A member of the AstraZeneca Group, and an employee of AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.